Japan's day, wrapped and delivered by morning.
Latest Tokyo Brief coverage on GNI Group Ltd., tracking filings, financial news, and market signals from Japan.
TSE:2160
The US registration covers Gyre shares issued in the Cullgen buyout, not fresh fundraising, and parent GNI says its effective interest stands at about 70 per cent with no material effect expected on consolidated results.
GNI plans to buy all of Ayumi Pharmaceutical Holdings for ¥44.776 billion and make it a wholly owned unit, arguing the deal adds a steadier Japanese earnings base plus an established sales network in rheumatology, orthopedics and fever-and-pain drugs. Ayumi reported revenue of ¥38.543 billion and operating profit of ¥6.206 billion in the year to March 2026, giving GNI a domestic commercial platform rather than just another pipeline promise. The financing is the real tell. GNI will pay ¥18.005 billion in cash and settle ¥26.771 billion through a contribution in kind, issuing 9,974,291 new shares to the sellers, while also lining up ¥20 billion of borrowing from Mizuho Bank and SBI Shinsei Bank. Management says the deal should close between June 30 and September 30, but existing holders face 17.89% share dilution and BCP is expected to emerge as the largest shareholder.